REFERENCES
1. Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
2. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269-88.
3. Nagarajah S. Exosome secretion - more than simple waste disposal? Implications for physiology, diagnostics and therapeutics. J Circ Biomark. 2016;5:7.
5. Li Q, Ding Y, Shi Y, et al. 80 years of extracellular vesicles: from discovery to clinical translation. Extracell Vesicles Circ Nucl Acids. 2026;7:165-233.
6. Zabeo D, Cvjetkovic A, Lässer C, Schorb M, Lötvall J, Höög JL. Exosomes purified from a single cell type have diverse morphology. J Extracell Vesicles. 2017;6:1329476.
7. Zhang Y, Meng X, Greening DW, et al. Unveiling heterogeneity: innovations and challenges in single-vesicle analysis for clinical translation. J Extracell Vesicles. 2025;14:e70209.
8. Chaudhary PK, Kim S, Kim S. Shedding light on the cell biology of platelet-derived extracellular vesicles and their biomedical applications. Life. 2023;13:1403.
9. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
10. Lawson C, Vicencio JM, Yellon DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol. 2016;228:R57-71.
11. Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27:585-98.
12. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262:9412-20.
13. Johnstone RM. Revisiting the road to the discovery of exosomes. Blood Cells Mol Dis. 2005;34:214-9.
14. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654-9.
15. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-6.
16. Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim Biophys Acta. 2014;1841:108-20.
17. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303.
18. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4:594-600.
19. Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382-6.
20. Barile L, Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63-78.
21. Hergenreider E, Heydt S, Tréguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012;14:249-56.
22. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172-7.
23. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341-5.
24. Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584-93.
25. Thompson AG, Gray E, Heman-Ackah SM, et al. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol. 2016;12:346-57.
26. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14:195-208.
27. Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748-59.
28. Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087.
29. Vergauwen G, Tulkens J, Pinheiro C, et al. Robust sequential biophysical fractionation of blood plasma to study variations in the biomolecular landscape of systemically circulating extracellular vesicles across clinical conditions. J Extracell Vesicles. 2021;10:e12122.
30. Dooley K, McConnell RE, Xu K, et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol Ther. 2021;29:1729-43.
31. Jang SC, Economides KD, Moniz RJ, et al. ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. Commun Biol. 2021;4:497.
32. Kamerkar S, Leng C, Burenkova O, et al. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Sci Adv. 2022;8:eabj7002.
33. Schwarz G, Ren X, Xie W, Guo H, Jiang Y, Zhang J. Engineered exosomes: a promising drug delivery platform with therapeutic potential. Front Mol Biosci. 2025;12:1583992.
34. Dave KM, Pinky PP, S Manickam D. Molecular engineering of extracellular vesicles for drug delivery: strategies, challenges, and perspectives. J Control Release. 2025;386:114068.
35. Wu J, Jin Z, Fu T, et al. Extracellular vesicle-based drug delivery systems in cancer therapy. Int J Mol Sci. 2025;26:4835.
36. Center for Drug Evaluation, National Medical Products Administration. Scope, classification and interpretation of advanced therapy medicinal products (draft for comments). Available from: https://www.ydcdei.org.cn/news/show/1130131706796584960. [Last accessed on 24 Aug 2026].
37. Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001;107:1395-402.
38. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-5.
39. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367-8.
40. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661-9.
41. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214-22.
42. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-19.
43. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20:1053-67.
44. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18:1852.
45. Willis CM, Nicaise AM, Peruzzotti-Jametti L, Pluchino S. The neural stem cell secretome and its role in brain repair. Brain Res. 2020;1729:146615.
46. Gong M, Yu B, Wang J, et al. Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget. 2017;8:45200-12.
47. Liang X, Zhang L, Wang S, Han Q, Zhao RC. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci. 2016;129:2182-9.
48. Zhu Y, Liao ZF, Mo MH, Xiong XD. Mesenchymal stromal cell-derived extracellular vesicles for vasculopathies and angiogenesis: therapeutic applications and optimization. Biomolecules. 2023;13:1109.
49. Tejeda-Mora H, Leon LG, Demmers J, et al. Proteomic analysis of mesenchymal stromal cell-derived extracellular vesicles and reconstructed membrane particles. Int J Mol Sci. 2021;22:12935.
50. Abyadeh M, Mirshahvaladi S, Kashani SA, et al. Proteomic profiling of mesenchymal stem cell-derived extracellular vesicles: impact of isolation methods on protein cargo. J Extracell Biol. 2024;3:e159.
51. Krishnan I, Chan AML, Law JX, Ng MH, Jayapalan JJ, Lokanathan Y. Proteomic analysis of umbilical cord mesenchymal stem cell-derived extracellular vesicles: a systematic review. Int J Mol Sci. 2024;25:5340.
52. Nakamura Y, Kita S, Tanaka Y, et al. Adiponectin stimulates exosome release to enhance mesenchymal stem-cell-driven therapy of heart failure in mice. Mol Ther. 2020;28:2203-19.
53. Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10:301-12.
54. Shabbir A, Cox A, Rodriguez-Menocal L, Salgado M, Van Badiavas E. Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro. Stem Cells Dev. 2015;24:1635-47.
55. Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med. 2014;92:387-97.
56. Deng H, Zhu L, Zhang Y, et al. Differential lung protective capacity of exosomes derived from human adipose tissue, bone marrow, and umbilical cord mesenchymal stem cells in sepsis-induced acute lung injury. Oxid Med Cell Longev. 2022;2022:7837837.
57. Wang X, Liu D, Zhang X, Yang L, Xia Z, Zhang Q. Exosomes from adipose-derived mesenchymal stem cells alleviate sepsis-induced lung injury in mice by inhibiting the secretion of IL-27 in macrophages. Cell Death Discov. 2022;8:18.
58. Wang N, Chen C, Yang D, et al. Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis. Biochim Biophys Acta Mol Basis Dis. 2017;1863:2085-92.
59. Teo KYW, Zhang S, Loh JT, et al. Mesenchymal stromal cell exosomes mediate M2-like macrophage polarization through CD73/Ecto-5’-nucleotidase activity. Pharmaceutics. 2023;15:1489.
60. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30:1575-8.
61. Diederichs S, Shine KM, Tuan RS. The promise and challenges of stem cell-based therapies for skeletal diseases: stem cell applications in skeletal medicine: potential, cell sources and characteristics, and challenges of clinical translation. Bioessays. 2013;35:220-30.
62. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19:998-1004.
63. Gimona M, Pachler K, Laner-Plamberger S, Schallmoser K, Rohde E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int J Mol Sci. 2017;18:1190.
64. Busatto S, Vilanilam G, Ticer T, et al. Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells. 2018;7:273.
65. Bahr MM, Amer MS, Abo-El-Sooud K, Abdallah AN, El-Tookhy OS. Preservation techniques of stem cells extracellular vesicles: a gate for manufacturing of clinical grade therapeutic extracellular vesicles and long-term clinical trials. Int J Vet Sci Med. 2020;8:1-8.
66. Rani S, Ryan AE, Griffin MD, Ritter T. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther. 2015;23:812-23.
67. Showalter MR, Wancewicz B, Fiehn O, et al. Primed mesenchymal stem cells package exosomes with metabolites associated with immunomodulation. Biochem Biophys Res Commun. 2019;512:729-35.
68. Yang R, Huang H, Cui S, Zhou Y, Zhang T, Zhou Y. IFN-γ promoted exosomes from mesenchymal stem cells to attenuate colitis via miR-125a and miR-125b. Cell Death Dis. 2020;11:603.
69. Xu G, Jin J, Fu Z, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct Target Ther. 2025;10:255.
70. Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989;37:871-99.
71. Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41:733-55.
72. Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117-34.
73. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078-94.
75. Ikawa T, Yano K, Watanabe N, Masamune K, Yamato M. Non-clinical assessment design of autologous chondrocyte implantation products. Regen Ther. 2015;1:98-108.
76. Chevillet JR, Kang Q, Ruf IK, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A. 2014;111:14888-93.
77. Wei Z, Batagov AO, Schinelli S, et al. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun. 2017;8:1145.
78. Kang M, Jordan V, Blenkiron C, Chamley LW. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021;10:e12085.
79. Aimaletdinov AM, Gomzikova MO. Tracking of extracellular vesicles’ biodistribution: new methods and approaches. Int J Mol Sci. 2022;23:11312.
80. Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov. 2022;21:379-99.
81. Lau SY, Kang M, Hisey CL, Chamley LW. Studying exogenous extracellular vesicle biodistribution by in vivo fluorescence microscopy. Dis Model Mech. 2023;16:dmm050074.
82. Welsh JA, Goberdhan DCI, O’Driscoll L, et al. ; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
83. Royo F, Cossío U, Ruiz de Angulo A, Llop J, Falcon-Perez JM. Modification of the glycosylation of extracellular vesicles alters their biodistribution in mice. Nanoscale. 2019;11:1531-7.
84. Imai T, Takahashi Y, Nishikawa M, et al. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles. 2015;4:26238.
85. Matsumoto A, Takahashi Y, Chang HY, et al. Blood concentrations of small extracellular vesicles are determined by a balance between abundant secretion and rapid clearance. J Extracell Vesicles. 2020;9:1696517.
86. Kooijmans SAA, Fliervoet LAL, van der Meel R, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016;224:77-85.
87. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-92.
88. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84.
89. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653-64.
90. Rodrigues G, Hoshino A, Kenific CM, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21:1403-12.
91. Choi H, Kim MY, Kim DH, et al. Quantitative biodistribution and pharmacokinetics study of GMP-grade exosomes labeled with (89)Zr radioisotope in mice and rats. Pharmaceutics. 2022;14:1118.
92. Tamasi V, Németh K, Csala M. Role of extracellular vesicles in liver diseases. Life. 2023;13:1117.
93. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3:24641.
94. Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21:9-17.
95. Joshi BS, de Beer MA, Giepmans BNG, Zuhorn IS. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano. 2020;14:4444-55.
96. Ribovski L, Joshi B, Gao J, Zuhorn I. Breaking free: endocytosis and endosomal escape of extracellular vesicles. Extracell Vesicles Circ Nucl Acids. 2023;4:283-305.
97. Ginini L, Billan S, Fridman E, Gil Z. Insight into extracellular vesicle-cell communication: from cell recognition to intracellular fate. Cells. 2022;11:1375.
98. Schlich M, Palomba R, Costabile G, et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl Med. 2021;6:e10213.
99. Hagedorn L, Jürgens DC, Merkel OM, Winkeljann B. Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design. Extracell Vesicles Circ Nucl Acids. 2024;5:344-57.
100. Somiya M, Kuroda S. Reporter gene assay for membrane fusion of extracellular vesicles. J Extracell Vesicles. 2021;10:e12171.
101. Armstrong JP, Holme MN, Stevens MM. Re-engineering extracellular vesicles as smart nanoscale therapeutics. ACS Nano. 2017;11:69-83.
102. Zheng W, Rädler J, Sork H, et al. Identification of scaffold proteins for improved endogenous engineering of extracellular vesicles. Nat Commun. 2023;14:4734.
103. Zhao H, Li Z, Liu D, et al. PlexinA1 (PLXNA1) as a novel scaffold protein for the engineering of extracellular vesicles. J Extracell Vesicles. 2024;13:e70012.
104. Piffoux M, Volatron J, Cherukula K, et al. Engineering and loading therapeutic extracellular vesicles for clinical translation: a data reporting frame for comparability. Adv Drug Deliv Rev. 2021;178:113972.
105. Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498-503.
106. Matsumoto A, Takahashi Y, Nishikawa M, et al. Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected B16BL6-derived exosomes by macrophages. J Pharm Sci. 2017;106:168-75.
107. Matsumoto A, Takahashi Y, Ogata K, et al. Phosphatidylserine-deficient small extracellular vesicle is a major somatic cell-derived sEV subpopulation in blood. iScience. 2021;24:102839.
108. Gong L, Tian L, Cui K, et al. An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy. J Control Release. 2023;364:672-86.
109. Cheng Q, Dai Z, Smbatyan G, Epstein AL, Lenz HJ, Zhang Y. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther. 2022;30:3066-77.
110. Giudice AM, Matlaga S, Roth SL, et al. Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma. Sci Transl Med. 2025;17:eads4214.
111. Liu Z, Chen Y, Cao Y, et al. A dually nanobody-engineered milk-derived extracellular vesicle nanomedicine targeting tumour-associated macrophages and cancer cells for cancer therapy. J Extracell Vesicles. 2026;15:e70236.
112. Wang Y, Chen X, Tian B, et al. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics. 2017;7:1360-72.
113. Meng WT, Zhu J, Wang YC, et al. Targeting delivery of miR-146a via IMTP modified milk exosomes exerted cardioprotective effects by inhibiting NF-κB signaling pathway after myocardial ischemia-reperfusion injury. J Nanobiotechnology. 2024;22:382.
114. Yu D, Ding Q, Xiang C, et al. NIR-II engineered exosome nanotheranostic probes for “oriented blasting” in orthotopic glioblastoma. ACS Nano. 2025;19:22900-13.
115. Yue X, Cui J, Ren S, et al. NK-cell-derived extracellular vesicles engineered to carry senolytics eliminate chemotherapy-induced senescent osteosarcoma cells. J Extracell Vesicles. 2025;14:e70123.
116. Xie Y, Liu Q, Tan J, et al. CAP-CD56+CD271+ BMSCs exos-loaded PVA/SA sustained-release hydrogel attenuates chondrocyte senescence and ameliorates lumbar facet joint osteoarthritis. Bioact Mater. 2026;57:73-92.
117. Huang SW, Lin YC, Pan CM, et al. CD3ɛ nanobody-engineered extracellular vesicles driving in vivo generation of TCE-secreting CAR-Ts for solid tumor therapy with memory response and minimal immunogenicity. Adv Sci. 2026;13:e19440.
118. Somiya M, Kuroda S. Real-time luminescence assay for cytoplasmic cargo delivery of extracellular vesicles. Anal Chem. 2021;93:5612-20.
119. Bui S, Dancourt J, Lavieu G. Virus-free method to control and enhance extracellular vesicle cargo loading and delivery. ACS Appl Bio Mater. 2023;6:1081-91.
120. Vanherle S, Guns J, Loix M, et al. Extracellular vesicle-associated cholesterol supports the regenerative functions of macrophages in the brain. J Extracell Vesicles. 2023;12:e12394.
121. Maguire CA, Balaj L, Sivaraman S, et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther. 2012;20:960-71.
122. Zhang Y, Wu J, Zhang H, Wei J, Wu J. Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor. Front Bioeng Biotechnol. 2020;8:574007.
123. Wang X, Munson MJ, Friis K, et al. Hybrid extracellular vesicles for efficient loading and functional delivery of mRNA. J Extracell Vesicles. 2025;14:e70201.
124. Wang Q, Yu J, Kadungure T, Beyene J, Zhang H, Lu Q. ARMMs as a versatile platform for intracellular delivery of macromolecules. Nat Commun. 2018;9:960.
125. Dong S, Liu X, Bi Y, et al. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nat Commun. 2023;14:6610.
126. Zickler AM, Liang X, Gupta D, et al. Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles. Adv Sci. 2024;11:e2407619.
127. Liang X, Gupta D, Xie J, et al. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nat Commun. 2025;16:4028.
128. Bach P, Kamphuis E, Odermatt B, Sutter G, Buchholz CJ, Kalinke U. Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol. 2007;178:5839-47.
129. Temchura VV, Tenbusch M, Nchinda G, et al. Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus. Vaccine. 2008;26:3662-72.
130. Munis AM, Mattiuzzo G, Bentley EM, Collins MK, Eyles JE, Takeuchi Y. Use of heterologous vesiculovirus G proteins circumvents the humoral anti-envelope immunity in lentivector-based in vivo gene delivery. Mol Ther Nucleic Acids. 2019;17:126-37.
131. Colao IL, Corteling R, Bracewell D, Wall I. Manufacturing exosomes: a promising therapeutic platform. Trends Mol Med. 2018;24:242-56.
132. Grangier A, Branchu J, Volatron J, et al. Technological advances towards extracellular vesicles mass production. Adv Drug Deliv Rev. 2021;176:113843.
133. Gong C, Tian J, Wang Z, et al. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J Nanobiotechnology. 2019;17:93.
134. Yang X, Xu Q, Wang J, et al. Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies. Exp Hematol Oncol. 2026;15:21.
135. Codiak B. Codiak BioSciences announces program reprioritization and corporate restructuring. 2022. Available from: https://www.biospace.com/codiak-biosciences-announces-program-reprioritization-and-corporate-restructuring. [Last accessed on 24 Aug 2026].
136. Kalluri VS, Smaglo BG, Mahadevan KK, et al. Engineered exosomes with Kras(G12D) specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat Commun. 2025;16:8696.
137. Hyun S, Choi H, Sub Y, et al. Safety and anti-inflammatory effects of engineered extracellular vesicles (ILB-202) for NF-κB inhibition: a double-blind, randomized, placebo-controlled phase 1 trial. J Extracell Vesicles. 2025;14:e70141.
138. Grigoropoulos I, Tsioulos G, Kastrissianakis A, et al. The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS. Respir Res. 2024;25:151.
139. Codiak B. Codiak BioSciences to pursue asset sale through voluntary Chapter 11 process. 2023. Available from: https://www.sec.gov/Archives/edgar/data/1659352/000119312523079964/d467120dex991.htm. [Last accessed on 24 Aug 2026].
140. Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.
141. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.
142. Adlerz K, Patel D, Rowley J, Ng K, Ahsan T. Strategies for scalable manufacturing and translation of MSC-derived extracellular vesicles. Stem Cell Res. 2020;48:101978.
143. Phelps J, Sanati-Nezhad A, Ungrin M, Duncan NA, Sen A. Bioprocessing of mesenchymal stem cells and their derivatives: toward cell-free therapeutics. Stem Cells Int. 2018;2018:9415367.
144. Finn, Phd J, Konstantinov, Phd K. Exosome-based therapeutics: ready for prime time. Cell Gene Therapy Insights. 2020;6:597-605.
145. Ng KS, Smith JA, McAteer MP, et al. Bioprocess decision support tool for scalable manufacture of extracellular vesicles. Biotechnol Bioeng. 2019;116:307-19.
146. Jeyaram A, Jay SM. Preservation and storage stability of extracellular vesicles for therapeutic applications. AAPS J. 2017;20:1.
